The FTSE 100’s Hottest Growth Stocks: GlaxoSmithKline plc

Royston Wild explains why GlaxoSmithKline plc (LON: GSK) is an exceptional earnings selection.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am outlining why GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) could be considered a terrific stock for growth hunters.

Pipeline pulling out the stops

The business of drugs testing can never provide the prescription for guaranteed earnings growth, where even the slight delay in getting product to market can result in a huge earnings dent. But in my opinion, GlaxoSmithKline’s terrific record of getting its drugs from lab bench to pharmacy counter makes it an excellent pick for those seeking decent growth prospects.

Indeed, the firm’s ViiV Healthcare subsidiary received European Commission approval for its anti-HIV product Triumeq earlier this month, and follows on from US Food and Drug Administration’s authorisation in August. The revolutionary, triple-combination single pill is GlaxoSmithKlineexpected to experience huge demand from sufferers of the disease.

Elsewhere, the Brentford-based company also received positive Phase III data for its monoclonal antibody mepolizumab. The tests displayed terrific success in helping patients suffering the effects of chronic asthma, and GlaxoSmithKline advised it will be filing for marketing approval by the close of the year.

With more than 40 more products up its sleeve in late-stage testing, I reckon that GlaxoSmithKline is in great shape to finally hurdle the effect of a steady stream of patent lapses across key products and deliver the next generation of revenues-drivers for coming years.

Meanwhile GlaxoSmithKline is also enjoying stunning sales performance in emerging markets. The company’s reputation has been tarnished by ongoing corruption allegations in these new marketplaces more recently, however, and in particular China where sales rattled 25% lower during January-June to £129m due to ongoing investigations there.

But the company’s suite of industry-leading products continues to be swept up in developing regions on the back of hefty population growth and rising economic might. Indeed, GlaxoSmithKline saw Pharmaceuticals and Vaccines sales surge 11% higher in the first half to £822m, even in light of the ongoing travails in Beijing.

And should the company favourably resolve its current troubles in China, I expect sales to thrust still higher in these key growth markets.

Earnings snapback expected from next year

Due to the effect of enduring patent expirations, GlaxoSmithKline is anticipated to experience a hefty 16% earnings decline in the current financial year, to 94.9p per share. But City analysts expect the firm’s pipeline to produce a turnaround to the tune of 5% in 2015, to 100p.

And these projections leave the pharma giant dealing on attractive P/E multiples for this period, with a P/E rating of 15.1 times prospective earnings for 2014 — just above the yardstick of 15 which indicates decent value for money — and which slips to just 14.3 for next year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »